You just read:

Glenmark Pharmaceuticals' Experimental GBR 1302-BEAT™ Demonstrates Potent Anti-Tumor Activity in Preclinical Data Presented at the ESMO Symposium on Immuno-Oncology

News provided by

Glenmark Pharmaceuticals

Nov 04, 2016, 14:17 ET